Logo image of TNON

TENON MEDICAL INC (TNON) Stock Fundamental Analysis

NASDAQ:TNON - Nasdaq - US88066N3035 - Common Stock - Currency: USD

1.39  -0.07 (-4.78%)

After market: 1.3899 0 (-0.01%)

Fundamental Rating

3

TNON gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. While TNON seems to be doing ok healthwise, there are quite some concerns on its profitability. TNON is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TNON has reported negative net income.
TNON had a negative operating cash flow in the past year.
TNON had negative earnings in each of the past 5 years.
In the past 5 years TNON always reported negative operating cash flow.
TNON Yearly Net Income VS EBIT VS OCF VS FCFTNON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

TNON's Return On Assets of -105.22% is on the low side compared to the rest of the industry. TNON is outperformed by 84.57% of its industry peers.
TNON has a worse Return On Equity (-167.50%) than 74.47% of its industry peers.
Industry RankSector Rank
ROA -105.22%
ROE -167.5%
ROIC N/A
ROA(3y)-164.07%
ROA(5y)-166.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TNON Yearly ROA, ROE, ROICTNON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

TNON has a Gross Margin of 57.83%. This is comparable to the rest of the industry: TNON outperforms 53.72% of its industry peers.
In the last couple of years the Gross Margin of TNON has declined.
TNON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.32%
GM growth 5YN/A
TNON Yearly Profit, Operating, Gross MarginsTNON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

TNON does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNON has less shares outstanding
TNON has a worse debt/assets ratio than last year.
TNON Yearly Shares OutstandingTNON Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
TNON Yearly Total Debt VS Total AssetsTNON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -8.97, we must say that TNON is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.97, TNON is doing worse than 77.66% of the companies in the same industry.
There is no outstanding debt for TNON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.97
ROIC/WACCN/A
WACC8.68%
TNON Yearly LT Debt VS Equity VS FCFTNON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 3.52 indicates that TNON has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.52, TNON is in the better half of the industry, outperforming 63.83% of the companies in the same industry.
TNON has a Quick Ratio of 3.33. This indicates that TNON is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.33, TNON is in the better half of the industry, outperforming 70.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 3.33
TNON Yearly Current Assets VS Current LiabilitesTNON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.81% over the past year.
TNON shows a strong growth in Revenue. In the last year, the Revenue has grown by 38.47%.
TNON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 318.31% yearly.
EPS 1Y (TTM)78.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.92%
Revenue 1Y (TTM)38.47%
Revenue growth 3Y318.32%
Revenue growth 5YN/A
Sales Q2Q%-6.04%

3.2 Future

Based on estimates for the next years, TNON will show a very strong growth in Earnings Per Share. The EPS will grow by 24.15% on average per year.
TNON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.88% yearly.
EPS Next Y78.34%
EPS Next 2Y37.73%
EPS Next 3Y24.15%
EPS Next 5YN/A
Revenue Next Year16.93%
Revenue Next 2Y53.04%
Revenue Next 3Y41.88%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TNON Yearly Revenue VS EstimatesTNON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M
TNON Yearly EPS VS EstimatesTNON Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TNON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNON Price Earnings VS Forward Price EarningsTNON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNON Per share dataTNON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

A more expensive valuation may be justified as TNON's earnings are expected to grow with 24.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.73%
EPS Next 3Y24.15%

More info and screens

0

5. Dividend

5.1 Amount

TNON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TENON MEDICAL INC

NASDAQ:TNON (2/21/2025, 8:00:01 PM)

After market: 1.3899 0 (-0.01%)

1.39

-0.07 (-4.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-10 2025-03-10/amc
Inst Owners11.08%
Inst Owner Change17.15%
Ins Owners3.59%
Ins Owner Change0%
Market Cap4.36M
Analysts82.5
Price Target10.2 (633.81%)
Short Float %5.73%
Short Ratio1.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.9%
Min EPS beat(2)7.83%
Max EPS beat(2)15.97%
EPS beat(4)4
Avg EPS beat(4)21.01%
Min EPS beat(4)7.83%
Max EPS beat(4)51.69%
EPS beat(8)7
Avg EPS beat(8)16.98%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-14.91%
Min Revenue beat(2)-26.94%
Max Revenue beat(2)-2.88%
Revenue beat(4)0
Avg Revenue beat(4)-16.31%
Min Revenue beat(4)-26.94%
Max Revenue beat(4)-2.88%
Revenue beat(8)0
Avg Revenue beat(8)-14.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-54.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-268.12%
EPS NY rev (1m)0%
EPS NY rev (3m)14.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.32
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-27.23
EYN/A
EPS(NY)-8.03
Fwd EYN/A
FCF(TTM)-3.09
FCFYN/A
OCF(TTM)-2.99
OCFYN/A
SpS1.06
BVpS2.61
TBVpS2.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.22%
ROE -167.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.83%
FCFM N/A
ROA(3y)-164.07%
ROA(5y)-166.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 82.03%
Cap/Sales 9.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 3.33
Altman-Z -8.97
F-Score5
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)66.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.92%
EPS Next Y78.34%
EPS Next 2Y37.73%
EPS Next 3Y24.15%
EPS Next 5YN/A
Revenue 1Y (TTM)38.47%
Revenue growth 3Y318.32%
Revenue growth 5YN/A
Sales Q2Q%-6.04%
Revenue Next Year16.93%
Revenue Next 2Y53.04%
Revenue Next 3Y41.88%
Revenue Next 5YN/A
EBIT growth 1Y33.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.21%
OCF growth 3YN/A
OCF growth 5YN/A